A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
Combating glioblastoma remains a major challenge due the complex nature of these tumors, the inability of drugs to penetrate the brain tissue, and lack of correlation between animal models and the human condition.
Fast-breeding zebrafish, combined with fluorescent tagging, could be a powerful way to find new cancer drugs. This study tested >3,800 drugs in high-throughput fashion and found that retinoic acid, best known as an acne treatment, may be effective for adenoid cystic carcinoma. A clinical trial is now being planned at the Dana-Farber Cancer Institute.
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study that involved tests on mice researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic colitis with regular insulin. The researchers have set up a company with a view to testing the treatment and hopefully making it available to patients.
The internet of things (IoT) is allowing scientists to optimize laboratory operations and combine instruments to measure and respond to complex experimental conditions. As a result, IoT is enabling more detailed and more complex experimental designs.
New 3D maps of water distribution during cellular membrane fusion are accelerating scientific understanding of cell development, which could lead to new treatments for diseases associated with cell fusion. Using neutron diffraction at the Department of Energy's Oak Ridge National Laboratory, researchers have made the first direct observations of water in lipid bilayers used to model cell membrane fusion.
A head-to-head trial comparing the decades-old steroid, prednisone, and a promising new steroid, vamorolone, finds both act on the same key set of genetic pathways involved in controlling inflammation, indicates a new study led by Children's National Health System researchers. However, the study suggests the new investigational steroid doesn't activate several additional pathways involved in prednisone's bevy of undesirable side effects.
Using a bioinformatics approach, University of California San Diego School of Medicine researchers found that CD4+ T cell's binding partner, a molecule called MHC-II, may have even more influence on emerging tumors than MHC-I, the better known partner of CD8+ T cells. The finding, published September 20 in Cell, may help researchers improve cancer immunotherapies and predict which patients will respond best.
Attention has focused on how NSAIDs may cause dysfunction of the immune system. Researchers now have found that sub-acute pretreatment with the NSAID carprofen before experimental heart attack in mice impaired resolution of acute inflammation following cardiac injury. They focused on three aspects of the inflammation resolution axis -- cardiac function, leukocyte profiling and inflammation-resolution markers.
In search of an option for the drug known for causing several side effects, scientists describe the anti-inflammatory properties of protein galectin-1 in tests with rats involving ischemia-reperfusion scenarios.